Novo Nordisk A/S (NYSE:NVO) Position Increased by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 9,521.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 343,389 shares of the company's stock after purchasing an additional 339,820 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.'s holdings in Novo Nordisk A/S were worth $24,219,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $29,000. Finally, Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $33,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.97 during midday trading on Friday, reaching $64.32. 8,032,293 shares of the company traded hands, compared to its average volume of 7,363,987. The firm has a market cap of $287.19 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.26 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm's 50 day simple moving average is $70.37 and its two-hundred day simple moving average is $74.53. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion during the quarter. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.